2023 Public Policy Comments

• January 31, 2023 – OCAN Comment Letter to HHS CMS on Obesity Care in Essential Health Benefits
• February 16, 2023 – OAC Letter of Support for CT legislation – SB 977 Medical Assistance for Surgery and Medical Services Related to Treatment of Obesity
• March 5, 2023 – OAC Supports Passage of House Bill 1315/Senate Bill 674 to Expand Coverage of Anti-Obesity Medications for TennCare Beneficiaries
• April 26, 2023 – OAC Comments to Members of the Teacher Retirement System (TRS) Board of Trustees
• April 27, 2023 – OAC/ADA Comments to Wisconsin ETF Group Insurance Board re State Employee Coverage of Obesity Care
• May 10, 2023 – OAC Supports Ohio Department of Medicaid coverage for evidence-based obesity treatments
• May 15, 2023 – OAC encourages the Utah Department of Health and Human Services, Pharmacy and Therapeutics (P&T) Committee to include FDA-Approved anti-obesity medications on the Medicaid Preferred Drug List Program
• June 14, 2023 – OAC comments on United State Preventive Services Task Force (USPSTF) draft research plan on Weight Loss to Prevent Obesity-Related Morbidity and Morbidity in Adults: Interventions
• June 16, 2023 – OAC partners with the American Diabetes Association in support of Massachusetts Senate Bill 754 by the Joint Committee on Health Care Financing to provide Medicaid access to comprehensive coverage for obesity treatments
• June 29, 2023 – OAC urges the Ohio Department of Medicaid to lift the regulatory restriction on coverage for anti-obesity medications and add anti-obesity medications as covered treatments
• August 2, 2023 – OAC and ADA Urge the Florida Agency for Healthcare Administration to Expand Medicaid coverage of Obesity Treatments